We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$10B
AUM Growth
+$66.4M
Cap. Flow
+$419M
Cap. Flow %
4.17%
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$282M
2
CELC icon
Celcuity
CELC
+$271M
3
ERAS icon
Erasca
ERAS
+$189M
4
TNGX icon
Tango Therapeutics
TNGX
+$164M
5
IRTC icon
iRhythm Holdings
IRTC
+$70.2M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$269M
2
AXSM icon
Axsome Therapeutics
AXSM
+$162M
3
PODD icon
Insulet
PODD
+$92.3M
4
MASI
Masimo
MASI
+$88.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$85.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
51
Evommune Inc
EVMN
$532M
$34.5M 0.34%
1,502,235
+218,564
+17% +$4.94M
SYK icon
52
Stryker
SYK
$130B
$32.9M 0.33%
100,000
-145,000
-59% -$52.1M
SVRA icon
53
Savara
SVRA
$1.11B
$32.5M 0.32%
5,952,380
– –
CADL icon
54
Candel Therapeutics
CADL
$859M
$31.5M 0.31%
+6,422,018
New +$34.9M
AQST icon
55
Aquestive Therapeutics
AQST
$533M
$30.8M 0.31%
7,426,471
+1,176,471
+19% +$4.77M
AKTS
56
Aktis Oncology
AKTS
$1.38B
$28.5M 0.28%
+1,592,043
New +$30.9M
NGNE icon
57
Neurogene
NGNE
$723M
$27.5M 0.27%
1,362,456
– –
CGEM icon
58
Cullinan Oncology
CGEM
$1.31B
$24.2M 0.24%
1,705,960
– –
CMPX icon
59
Compass Therapeutics
CMPX
$405M
$22.1M 0.22%
4,186,599
+1,686,599
+67% +$9.74M
DNTH icon
60
Dianthus Therapeutics
DNTH
$6.49B
$20.8M 0.21%
+248,063
New +$14.4M
FLGT icon
61
Fulgent Genetics
FLGT
$511M
$20.5M 0.2%
1,289,000
+583,973
+83% +$12.7M
BBNX
62
Beta Bionics
BBNX
$790M
$20M 0.2%
2,000,000
-500,000
-20% -$7.4M
KYMR icon
63
Kymera Therapeutics
KYMR
$9.76B
$20M 0.2%
240,000
– –
IPSC icon
64
Century Therapeutics
IPSC
$348M
$19.7M 0.2%
+8,695,652
New +$18.3M
BEAM icon
65
Beam Therapeutics
BEAM
$2.76B
$13.6M 0.14%
570,394
– –
AVTX icon
66
Avalo Therapeutics
AVTX
$1.05B
$12.8M 0.13%
+856,962
New +$13.4M
OCGN icon
67
Ocugen
OCGN
$458M
$12.1M 0.12%
+6,666,666
New +$11.5M
HTFL
68
Heartflow Inc
HTFL
$3.63B
$12M 0.12%
495,000
– –
WVE icon
69
Wave Life Sciences
WVE
$1.07B
$9.79M 0.1%
1,350,000
– –
PCSC
70
DELISTED
Perceptive Capital Solutions
PCSC
$8.15M 0.08%
742,500
– –
JBIO
71
Jade Biosciences
JBIO
$1.57B
$8.05M 0.08%
573,205
-876,068
-60% -$12.7M
CAPR icon
72
Capricor Therapeutics
CAPR
$385M
$7.6M 0.08%
250,000
– –
MIST icon
73
Milestone Pharmaceuticals
MIST
$137M
$7.53M 0.08%
6,331,001
+3,824,899
+153% +$6.7M
KLRS
74
Kalaris Therapeutics
KLRS
$97.1M
$7.5M 0.07%
1,300,000
– –
IVA
75
Inventiva
IVA
$1.09B
$7.21M 0.07%
1,298,702
+1
+0% +$6
1 2
3
4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q1 2026 Portfolio in Review

As of Q1 2026, RTW Investments held 98 positions worth $10B, up 0.67% from $9.98B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments deployed $419M of net new capital in Q1 2026, opening 7 new positions and adding to 30 existing holdings. Its largest new stake was Waystar Holding Corp: 1,630,000 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $85.8M trimmed.

  • RTW Investments's largest Q1 2026 buy was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
  • RTW Investments added most to CG Oncology in Q1 2026, an estimated $282M increase.
  • RTW Investments's biggest Q1 2026 reduction was Apellis Pharmaceuticals, cutting an estimated $85.8M.
  • RTW Investments fully exited Penumbra in Q1 2026, selling an estimated $269M.
  • RTW Investments's ten largest holdings make up 50% of its $10B portfolio in Q1 2026.
  • RTW Investments opened 7 new positions and closed 10 in Q1 2026.
  • RTW Investments's portfolio value rose 0.67% quarter-over-quarter to $10B.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.